Pharmaceuticals APAC

APAC PD-1 and PD-L1 Inhibitors Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC PD-1 and PD-L1 Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Drug, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $12.05 Bn Placeholder estimate
Estimate 2025 $13.25 Bn 22.3% of the global market
Projected 2034 $30.98 Bn 133.9% Adds $17.73 Bn over 9 forecast years
CAGR 2025–2034 9.9% Faster than 56% of 180 Pharmaceuticals markets here
Key players 6 +1
  • APAC is 22.3% of the global market.
  • Among regions, the largest is North America at $33.11 Bn.
  • Fastest growing: Africa at 10.8% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$17.73 Bn total, 2026–2034

Year-by-year market size, 2024–2034
PD-1 and PD-L1 Inhibitors Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $12.05 Bn — —
2025 (base) $13.25 Bn +$1.19 Bn —
2026 (forecast) $14.56 Bn +$1.31 Bn +9.9%
2027 (forecast) $16.00 Bn +$1.44 Bn +20.8%
2028 (forecast) $17.58 Bn +$1.58 Bn +32.7%
2029 (forecast) $19.32 Bn +$1.74 Bn +45.9%
2030 (forecast) $21.24 Bn +$1.91 Bn +60.3%
2031 (forecast) $23.34 Bn +$2.10 Bn +76.2%
2032 (forecast) $25.65 Bn +$2.31 Bn +93.6%
2033 (forecast) $28.19 Bn +$2.54 Bn +112.8%
2034 (forecast) $30.98 Bn +$2.79 Bn +133.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC PD-1 and PD-L1 Inhibitors Market Analysis at a glance
Market size, 2025$13.25 Bn placeholder estimate
Forecast, 2034$30.98 Bn placeholder estimate
Growth (CAGR), 2025–20349.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, indication and end user (see all)
Key playersMerck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, BeiGene and 1 more (see all)
Active clinical trials727 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC PD-1 and PD-L1 Inhibitors Market Analysis Executive Summary

PD-1 and PD-L1 inhibitors are checkpoint drugs that release the brakes on the immune system so it can attack cancer.

Key segments of the PD-1 and PD-L1 Inhibitors market include drug (Pembrolizumab, Nivolumab and Atezolizumab) and indication (Lung Cancer, Melanoma and Kidney Cancer).

Bar chart: Asia Pacific PD-1 and PD-L1 Inhibitors market size, 2024–2034, placeholder estimates. $12.05 Bn in 2024, $13.25 Bn in 2025 and $30.98 Bn in 2034, 9.9% CAGR.
Asia Pacific PD-1 and PD-L1 Inhibitors market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC PD-1 and PD-L1 Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the PD-1 and PD-L1 Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the PD-1 and PD-L1 Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the PD-1 and PD-L1 Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for PD-1 and PD-L1 Inhibitors Market in APAC

The PD-1 and PD-L1 Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for PD-1 and PD-L1 Inhibitors Market in APAC

PD-1 and PD-L1 Inhibitors in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], BPOM (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Drug Administration of Vietnam (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28]. ClinicalTrials.gov lists 727 studies on PD-1 and PD-L1 Inhibitors that are recruiting, active or about to start in APAC.⁠[29]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Drug Administration of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

[29] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for PD-1 and PD-L1 Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in PD-1 and PD-L1 Inhibitors right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

PD-1 and PD-L1 Inhibitors in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the PD-1 and PD-L1 Inhibitors market in Asia Pacific?
Placeholder estimate: about $13.25 Bn in 2025, rising to about $30.98 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the PD-1 and PD-L1 Inhibitors market in Asia Pacific growing?
Placeholder estimate: about 9.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the PD-1 and PD-L1 Inhibitors market report cover?
The report splits the market by drug (Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab and more), indication (Lung Cancer, Melanoma, Kidney Cancer, Other Solid Tumors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the PD-1 and PD-L1 Inhibitors market?
Key players include Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, BeiGene and Innovent Biologics.
What is driving the PD-1 and PD-L1 Inhibitors market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the PD-1 and PD-L1 Inhibitors market. Faster approvals and new combinations are improving survival.
How many clinical trials on PD-1 and PD-L1 Inhibitors are running in Asia Pacific?
727 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on PD-1 and PD-L1 Inhibitors?
PubMed lists 1,230 papers on PD-1 and PD-L1 Inhibitors added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on oncology

See the topic